Repositioning Candidate Details
| Candidate ID: | R0791 |
| Source ID: | DB05421 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | CP-122721 |
| Synonyms: | -- |
| Molecular Formula: | C20H23F3N2O2 |
| SMILES: | COC1=CC=C(OC(F)(F)F)C=C1CN[C@H]1CCCN[C@H]1C1=CC=CC=C1 |
| Structure: |
|
| DrugBank Description: | CP-122721, neurokinin 1 (NK1) antagonist is developed by Pfizer to treat depression, emesis, and inflammatory diseases including asthma and irritable bowel syndrome. |
| CAS Number: | 145742-28-5 |
| Molecular Weight: | 380.404 |
| DrugBank Indication: | Investigated for use/treatment in asthma, depression, and irritable bowel syndrome (IBS). |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | CP-122721 interacts with high affinity at the human NK1 receptor expressed in IM-9 cells. |
| Targets: | Neurokinin 1 receptor |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I17 | 1596 | Mental depression | Mental depression | disease of mental health/ cognitive disorder/ mood disorder | Details |
| I11 | 5295 | Intestinal disease | A gastrointestinal system disease that is located_in the intestine. http://en.wikipedia.org/wiki/Human_gastrointestinal_tract | disease of anatomical entity/gastrointestinal system disease | Details |